TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26841782

Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study: 24755888

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed-platinum (PC) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² d1) and either cisplatin (75 mg/m² d1) or carboplatin (AUC = 5 d1) plus gefitinib (PC-G)
Number of subjects: 0
Study: 22763078

Group type: EXPERIMENTAL
Intervention: eCG on Day 22 post AI (400 IU)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: hCG on Day 29 (2500 IU)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: eCG on Day 22 post AI (in low body condition cows)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 337
Study: 19692943

Group type: EXPERIMENTAL
Intervention: Evidence based medicine methodology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical protocol conducting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vital medicines listing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lists of refundable medicines
Number of subjects: 0
Study: 17999276

Group type: EXPERIMENTAL
Intervention: Estradiol supplementation during the luteal phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no estradiol supplementation)
Number of subjects: 0
Study: 15307690

Group type: EXPERIMENTAL
Intervention: Chinese medicine 'xiao cuo fang' combined with 0.1% adapalene gel
Number of subjects: 133

Group type: COMPARATOR
Intervention: 0.03% retinoic acid cream
Number of subjects: 133
Study: 12210667

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) program
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 85
Study: 9794097

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg/day, four times daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acipimox plus intralipid
Number of subjects: 50
Study: 11541496

Group type: EXPERIMENTAL
Intervention: Declarative preview group (verbal information about workload manipulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Procedural preview group (verbal information and practice under high-workload conditions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-preview group (no information about workload manipulation)
Number of subjects: 18
Study: 2572038

Group type: EXPERIMENTAL
Intervention: Broxaterol (0.6-1.2 mg/day by metered dose inhaler or 0.5-1.5 mg/day orally)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Broxaterol nebulizer solution
Number of subjects: 274

Group type: COMPARATOR
Intervention: Broxaterol by metered dose inhaler
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Broxaterol
Number of subjects: 274
Study: 20912

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg with diazepam and atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg with papaveretum and hyoscine
Number of subjects: 0
Study: 31452049

Group type: EXPERIMENTAL
Intervention: Dance-movement intervention (DMI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (life-as-usual)
Number of subjects: 99
Study: 27126617

Group type: EXPERIMENTAL
Intervention: Functional exercise+usual care group (n=32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care group (control, n=31)
Number of subjects: 63
Study: 26037626

Group type: EXPERIMENTAL
Intervention: Real electro-acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sham electro-acupuncture (non-insertion technique)
Number of subjects: 160
Study: 23951700

Group type: EXPERIMENTAL
Intervention: Dexpanthenol pastilles
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cold dissection technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thermal welding technique
Number of subjects: 120
Study: 22057874

Group type: EXPERIMENTAL
Intervention: Flex-Tip ETT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mallinckrodt Hi-Lo ETT
Number of subjects: 200
Study: 19832806

Group type: EXPERIMENTAL
Intervention: Asenapine 5 or 10 mg twice daily
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg once daily
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo/Asenapine
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 504
Study: 17256104

Group type: EXPERIMENTAL
Intervention: Er:YAG laser alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acid etching alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bur and etching
Number of subjects: 90
Study: 15072175

Group type: EXPERIMENTAL
Intervention: Interviewer administered CRQ (CRQ-IA)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Self-administered CRQ (CRQ-SA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standardised dyspnoea domain
Number of subjects: 71
Study: 11299062

Group type: EXPERIMENTAL
Intervention: Transfusion to a level of 100 g/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 0
Study: 9512851

Group type: EXPERIMENTAL
Intervention: Granisetron (2.5 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Droperidol (1.25 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 90
Study: 8736239

Group type: EXPERIMENTAL
Intervention: 5-micrograms dose of Pre S recombinant vaccine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of Pre S recombinant vaccine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Pre S recombinant vaccine
Number of subjects: 105
Study: 2323591

Group type: EXPERIMENTAL
Intervention: Cisapride (10 cases)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 cases)
Number of subjects: 20
Study: 7375913

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg daily for two or three weeks)
Number of subjects: 16
Study: 30797161

Group type: EXPERIMENTAL
Intervention: Focused-incentive group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split-incentive group
Number of subjects: 0
Study: 28904966

Group type: EXPERIMENTAL
Intervention: 1 μg/kg oral dexmedetomidine (DEX) in apple juice
Number of subjects: 100

Group type: COMPARATOR
Intervention: apple juice (control)
Number of subjects: 100
Study: 25825013

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment (1.8mg/day subcutaneously)
Number of subjects: 90
Study: 23347348

Group type: EXPERIMENTAL
Intervention: Flapless surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Flap surgery (control group)
Number of subjects: 24
Study: 21272039

Group type: EXPERIMENTAL
Intervention: Shampoo 1 (0.5% piroctone olamine and 0.45% climbazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shampoo 2 (1% zinc pyrithione)
Number of subjects: 0
Study: 19761715

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg) + Acetylsalicylic acid (325 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (325 mg) alone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg) alone
Number of subjects: 55
Study: 17634483

Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg daily in cohort 1
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg daily in cohort 2
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg daily in cohort 2
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily in cohort 3
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 1
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 1a
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 2
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Erlotinib clearance in cohort 3
Number of subjects: 55
Study: 14990394

Group type: EXPERIMENTAL
Intervention: Perindopril-based active treatment
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 11359552

Group type: EXPERIMENTAL
Intervention: Various interventions aimed at reducing medical errors (specific interventions not detailed)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control arms (no specific intervention detailed)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nonrandomized studies (24 studies evaluated for comparison)
Number of subjects: 13
Study: 9064950

Group type: EXPERIMENTAL
Intervention: Intracoronary iloprost (ILO) 0.5 ng kg‐1 min‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous iloprost (ILO) 2 ng kg‐1 min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Papaverine (PAPA) intracoronary
Number of subjects: 0
Study: 1473306

Group type: EXPERIMENTAL
Intervention: Combination therapy with ramipril 5 mg plus hydrochlorothiazide 25 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ramipril 5 mg monotherapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ramipril 10 mg monotherapy
Number of subjects: 165
Study: 6322827

Group type: EXPERIMENTAL
Intervention: Topical analgesia (4% lignocaine 2 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia (1.5%)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiopentone (10 mg kg‐1)
Number of subjects: 48
Study: 30536632

Group type: COMPARATOR
Intervention: Orally dispersible tablet (ODT) of racemic praziquantel (rac-PZQ) at 40 mg/kg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Orally dispersible tablet (ODT) of levo praziquantel (L-PZQ) at 20 mg/kg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Orally dispersible tablet (ODT) of levo praziquantel (L-PZQ)
Number of subjects: 68
Study: 29602534

Group type: EXPERIMENTAL
Intervention: Emotion recognition training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham intervention control
Number of subjects: 0
Study: 26561047

Group type: EXPERIMENTAL
Intervention: losartan (25 to 50 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: baseline to 2 years (donors)
Number of subjects: 30

Group type: COMPARATOR
Intervention: baseline to 2 years (recipients)
Number of subjects: 30
Study: 24451613

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 20
Study: 22075020

Group type: EXPERIMENTAL
Intervention: Spinal plus isoflurane anesthesia (SI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spinal plus desflurane anesthesia (SD)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spinal anesthesia alone (S)
Number of subjects: 45
Study: 21140355

Group type: EXPERIMENTAL
Intervention: Internal hemodiafiltration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-flux bicarbonate dialysis
Number of subjects: 24
Study: 17215654

Group type: EXPERIMENTAL
Intervention: Individual detailing intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group detailing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed guideline intervention
Number of subjects: 0
Study: 15465887

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg oral)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no ibuprofen)
Number of subjects: 11
Study: 12216077

Group type: EXPERIMENTAL
Intervention: Screened women (28,099)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Invited but declined screening (39,425)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Not invited (97,294)
Number of subjects: 28
Study: 10705093

Group type: EXPERIMENTAL
Intervention: Oral cancer information leaflet
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control groups (two control groups)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Knowledge questionnaire
Number of subjects: 259
Study: 8566937

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in LVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in LVV
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in MOL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor activity in RVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine in LVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine in MOL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in LVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in LVV
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in MOL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma epinephrine in RVP
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Plasma dopamine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: cAMP levels in all groups
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group beta-adrenoceptor density
Number of subjects: 69
Study: 2025378

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 7346742

Group type: EXPERIMENTAL
Intervention: methylphenidate (MPH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (AMP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo (PB)
Number of subjects: 12
Study: 30842175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study: 28117270

Group type: EXPERIMENTAL
Intervention: Supervised self-injection with an empty syringe
Number of subjects: 60

Group type: COMPARATOR
Intervention: Education only (control)
Number of subjects: 60
Study: 26275429

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 3517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 3517
Study: 24405624

Group type: EXPERIMENTAL
Intervention: TKA-GROUP (before TKA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TKA-GROUP (after TKA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: TKA-GROUP (pre-operative to post-operative)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CONTROL-GROUP
Number of subjects: 13
Study: 22276957

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment (KEY Laser(®) 3)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Sonic debridement (Sonicflex(®) 2003 L)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both treatments (Er:YAG laser and Sonic debridement)
Number of subjects: 78
Study: 19054817

Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 744
Study: 17584198

Group type: EXPERIMENTAL
Intervention: Doppler Echo, Doppler myocardial imaging, Strain rate imaging, transthoracic CFR after dipyridamole infusion, and brachial artery vasodilatation measurement in SSc patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transthoracic CFR
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Endothelial flow‐mediated dilatation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CFR and endothelial function
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chest-CT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Serological antibodies analysis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Systolic pulmonary pressure measurement
Number of subjects: 33
Study: 15028048

Group type: EXPERIMENTAL
Intervention: Atrially tracked pacing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rate-responsive pacing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 10
Study: 11311844

Group type: EXPERIMENTAL
Intervention: Games and shows aimed at a child's developmental level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Didactic information alone
Number of subjects: 0
Study: 9570235

Group type: EXPERIMENTAL
Intervention: Active Chinese herbal medication (CH-100), five tablets thrice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets, five tablets thrice daily
Number of subjects: 40
Study: 8072815

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently with DTPa and IPV
Number of subjects: 439
Study: 3211485

Group type: EXPERIMENTAL
Intervention: 1.0% suprofen solution
Number of subjects: 0
Study: 30539231

Group type: EXPERIMENTAL
Intervention: Flowering plants in the coronary care ward during index hospitalisation
Number of subjects: 122

Group type: COMPARATOR
Intervention: No plants (control) in the coronary care ward during index hospitalisation
Number of subjects: 122
Study: 28460263

Group type: EXPERIMENTAL
Intervention: Pressure mapping system
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard pressure ulcer prevention care (Control)
Number of subjects: 190
Study: 26001545

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR), 25% CR from baseline energy requirements
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caloric restriction combined with exercise (CR+exercise), 12.5% CR and 12.5% through aerobic exercise
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-calorie diet until 15% reduction in body weight followed by weight maintenance diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group, healthy weight maintenance
Number of subjects: 46
Study: 22591190

Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose (intended peak breath alcohol concentration of 0.04%)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 20186830

Group type: COMPARATOR
Intervention: Oral cyclophosphamide 130 mg/m(2) on Days 1 through 14 every 4 weeks for 12 cycles (C arm)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) on Days 1 and 8 every 4 weeks for 12 cycles (CMF arm)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Levamisole 5 mg weekly for 48 weeks (levamisole arm)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: No systemic therapy (control arm)
Number of subjects: 1146
Study: 17277584

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal activity (Control)
Number of subjects: 12
Study: 15892894

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 40
Study: 11856088

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole
Number of subjects: 175
Study: 10451908

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study: 7875466

Group type: EXPERIMENTAL
Intervention: Intestinal balloon distentions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transmucosal electrical nerve stimulation (15 Hz, 100 microseconds)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Somatic transcutaneous electrical nerve stimulation (100 Hz, 100 microseconds)
Number of subjects: 32
Study: 2092026

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amoxycillin (combined with ranitidine for ulcer healing)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dual therapy with both amoxycillin and TDB
Number of subjects: 29
Study: 350564

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 20
Study: 31386976

Group type: EXPERIMENTAL
Intervention: Hippotherapy on sand surface
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hippotherapy at faster horse walking speed (30%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hippotherapy on asphalt surface
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hippotherapy at slow (self-selected) horse walking speed
Number of subjects: 16
Study: 29629886

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Antiemetic prophylaxis
Number of subjects: 910
Study: 26610716

Group type: EXPERIMENTAL
Intervention: Positive outcome condition (adult completed the task successfully)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Negative outcome condition (adult did not complete the task successfully)
Number of subjects: 84
Study: 25066558

Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenia (nadir platelet count 100-149 × 10(9)/L)
Number of subjects: 7435

Group type: EXPERIMENTAL
Intervention: Severe thrombocytopenia (nadir platelet count <100 × 10(9)/L)
Number of subjects: 7435

Group type: COMPARATOR
Intervention: No thrombocytopenia
Number of subjects: 7435

Group type: EXPERIMENTAL
Intervention: Mild thrombocytopenia
Number of subjects: 7435

Group type: EXPERIMENTAL
Intervention: Severe thrombocytopenia
Number of subjects: 7435
Study: 22678087

Group type: EXPERIMENTAL
Intervention: QT prolongation on ECG immediately following SAH
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Tachycardia on baseline ECG
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: QT prolongation on ECG during the vasospasm risk period
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Tachycardia and ST changes
Number of subjects: 413
Study: 20685401

Group type: EXPERIMENTAL
Intervention: Atrial pacing with ventricular backup at 60 beats/min
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Ventricular backup pacing at 40 beats/min
Number of subjects: 1030
Study: 18569863

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) followed by 10 days of prasugrel 10 mg MD (n = 16)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg MD (n = 19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg MD (control)
Number of subjects: 39
Study: 15779502

Group type: EXPERIMENTAL
Intervention: CODAS formulation of verapamil (200 mg)
Number of subjects: 466